Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$68.97
-7.2%
$91.17
$57.30
▼
$155.29
$1.15B4.03309,790 shs252,126 shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-7.21%-17.20%-29.76%-33.45%-16.03%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$68.97
-7.2%
$91.17
$57.30
▼
$155.29
$1.15B4.03309,790 shs252,126 shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-7.21%-17.20%-29.76%-33.45%-16.03%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
2.50
Moderate Buy$185.00168.23% Upside

Current Analyst Ratings Breakdown

Latest INBX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
Lower Price TargetBuy$245.00 ➝ $220.00
9/18/2026
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
Reiterated RatingMarket Perform
9/11/2026
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
Reiterated RatingSell (D-)
8/27/2026
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
Reiterated RatingMarket Perform
8/24/2026
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
Initiated CoverageBuy$245.00
(Data available from 11/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$1.30M783.61N/AN/A($5.81) per share-11.87
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$140.05M-$9.06N/AN/AN/AN/A-563.90%-80.38%N/A

Latest INBX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/13/2026Q3 2026
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$2.45-$2.46-$0.01-$2.46$1.90 million$2.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/A
7.58
5.07

Institutional Ownership

CompanyInstitutional Ownership
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
82.46%

Insider Ownership

CompanyInsider Ownership
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
18.26%
CompanyEmployeesShares OutstandingFree FloatOptionable
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
11014.77 million12.07 millionOptionable

Recent News About These Companies

Inhibrx Biosciences (INBX) Jumped, So What Is Behind The Move?
HC Wainwright Has Bearish Estimate for INBX FY2026 Earnings
Research Analysts Set Expectations for INBX FY2026 Earnings
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Target Cut by HC Wainwright
Inhibrx Q3 Loss Widens
Inhibrx Reports Third Quarter 2026 Financial Results
How Inhibrx Biosciences Inc Com (INBX) Affects Rotational Strategy Timing

New MarketBeat Followers Over Time

Media Sentiment Over Time

Inhibrx Biosciences stock logo

Inhibrx Biosciences NASDAQ:INBX

$68.97 -5.36 (-7.21%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$69.14 +0.17 (+0.25%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.